Archive · 10 Aug 2026
Biodeal Pharmaceuticals Raises ₹385 Crore From RMB Capitalworks For Expansion And R&D
Biodeal Pharmaceuticals is a company that helps make medicines.
It has been doing this for about twenty years.
The company just got a lot of money, ₹385 crore, from another company called RMB Capitalworks.
This is the first time Biodeal has taken money from outside investors.
The money will be used to grow the business and to research and invent new medicines.
RMB is part of a big bank from South Africa called FirstRand Bank.
In return, RMB will own a secret part of the company.
Biodeal's leader, Anurag Kumar, says they plan to enter new areas and make new medicine ingredients.
The company earned ₹325 crore last year and hopes to earn much more in the coming years.
They want to earn ₹1,200 crore by the year 2030.
Biodeal Pharmaceuticals announced a ₹385 crore investment from RMB Capitalworks for business expansion and research and development.
This is the first equity raise by the two-decade-old contract development and manufacturing organisation.
RMB Capitalworks, a unit of South African lender FirstRand Bank, will receive an undisclosed stake in the company.
Biodeal reported ₹325 crore revenue with a 20 per cent operating profit margin in FY26.
The company aims to reach ₹500 crore revenue in FY27 and ₹1,200 crore by FY30 with new launches and expansion.
- Who
- Biodeal Pharmaceuticals, led by Chairman and Managing Director Anurag Kumar, and RMB Capitalworks, managed by Anshuman Malur.
- What
- RMB Capitalworks invested ₹385 crore in Biodeal Pharmaceuticals for expansion and R&D, taking an undisclosed stake.
- When
- Monday, August 10, 2026.
- Where
- Mumbai, India.
- Why
- To fund expansion into new segments, research and development of new molecules, and help Biodeal reach revenue targets of ₹500 crore in FY27 and ₹1,200 crore by FY30.
- Investment
- ₹385 crore
- Investor
- RMB Capitalworks
- Investee
- Biodeal Pharmaceuticals
- Investor parent
- FirstRand Bank (South Africa)
- Purpose
- Business expansion and R&D for new molecules
- FY26 revenue
- ₹325 crore
- FY26 operating profit margin
- 20%
- Revenue targets
- ₹500 crore (FY27); ₹1,200 crore (FY30)